Moreover, targeting the OCT4-DUSP6 pathway may offer a new therapeutic avenue for NSCLC, as evidenced by reduced tumor growth and lung tumor nodules in mice bearing OCT4-overexpressing A549 lung tumors after silencing DUSP6 expression. This evidence concerns the gene POU5F1 and neoplasm.